|
⚲
|
| Keyboard |
| Ardsley Advisory Partners
✚
|
|
|---|---|
| CRD # | 160595 |
| SEC # | 801-73664 |
| CIK # | 0000900529 |
| AUM | |
| Employees | 13 (54% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 203-564-4200 |
| Address | 262 Harbor Drive Stamford, CT 06902 |
| Source | [IAPD] [EDGAR] [Website] |
| Total AUM ($M) |
|---|
| Fees and Compensation — Form ADV Part 2A (1/23/2019) [Brochure] |
|---|
ITEM 5 – FEES AND COMPENSATION The Ardsley Funds offer private investment fund interests/shares only to certain qualified investors and admission to the Ardsley Funds is not open to the general public. Private investment fund interests/shares are sold only to qualified investors who are “Accredited Investors” under Rule 501 of Regulation D of the Securities Act of 1933, as amended, and “Qualified Eligible Persons” under Regulation 4.7 of the Commodity Exchange Act. Given the Ardsley Funds’ ownership restrictions, Ardsley has determined to limit the sale of private investment fund interests/shares to “Qualified Purchasers”; as such term is defined in Section 2(a) (51) of the Investment Company Act of 1940, as amended. Please refer to the applicable Fund’s PPMs for a complete description of that Fund’s fee schedule. Ardsley deducts fees from each Fund’s assets at the beginning of each fiscal quarter. In the case of a partial fiscal quarter; the Management Fee is calculated on a pro rata basis, based on the applicable percentage for the partial quarter and is repaid to the Fund and distributed to the investor. To the extent a capital contribution or withdrawal is made as of any day that is not the first day of a fiscal quarter, the Management Fee is prorated. Ardsley also charges performance based compensation in the form of an incentive allocation (the “Incentive Allocation”) for all Funds except the Advanced Healthcare Fund/Ridgecrest Fund. The Incentive Allocation is generally calculated each month and paid as of the last day of each fiscal year. Under the loss carryforward provision, generally an Investor will not be charged an Incentive Allocation until any net loss previously allocated to such Investor has been offset by subsequent net profits. Ardsley or the General Partner, in their respective sole discretion, may, in effect, waive, reduce or rebate the Management Fee or the Incentive Allocation for certain Investors. It should be noted that Ardsley employees and personnel do not pay an Incentive Allocation in connection with their investments in the Funds. Further, the Management Fee for all internal capital (i.e., an investment from an Ardsley employee and personnel) in the Funds is typically 0.50% (annualized). The Management Fee for all other Investors in the Ardsley Funds (except Ridgecrest Fund, which is not subject to a Management Fee) is typically 0.25% (annualized). The Funds’ PPMs set forth the fees and expenses to be paid by Investors. Prospective Investors should carefully review the PPMs and a Fund’s governing documents prior to investing in a Fund. Ardsley will bear all expenses incurred in connection with the offer and sale of interests in the Flagship Fund, Renewable Energy Fund, and the Healthcare Fund. The Ardsley Funds will also bear all legal, accounting expenses, administrative and all other operating expenses. The Funds bear all investment expenses, including interest expenses, brokerage commissions, custodial fees, taxes, expenses related to the purchase and sale of illiquid securities, and any other expenses which the General Partner reasonably determines should not be considered Administrative Expenses of the applicable Fund. It should also be noted that to the extent a trade error occurs, Fund losses caused by trade errors due to gross negligence, bad faith or willful misconduct on the part of Ardsley or its employees will be reversed with Ardsley being responsible to make the affected Funds whole. However, pursuant to Ardsley’s offering documents, the applicable Funds are required to bear the costs of any other trading errors. Investors in the Flagship Fund, may generally make withdrawals from their capital account in the Flagship Fund as follows: (i) at the end of any fiscal quarter, upon 45 days’ prior written notice, an Investor may withdraw up to 25% of its capital account; and (ii) at the end of any fiscal year, upon 30 days’ prior written notice, an Investor may withdraw any amount from their capital account. Investors in the Renewable Energy Fund can exercise 100% liquidity upon 30 days’ notice at the end of any quarter. Ardsley or the General Partner may require or permit the withdrawal of an Investor under such other circumstances as they, in their sole discretion, deem appropriate for any of the Funds. It is critical that Investors refer to their respective Fund’s offering documents for a complete understanding of how fees are calculated and deducted from their assets. The information contained herein is a summary only and is qualified in its entirety by the relevant Fund’s offering documents. |
| Account Minimums and Types of Clients — Form ADV Part 2A (1/23/2019) [Brochure] |
|---|
ITEM 7 – TYPES OF CLIENTS As described in Item 4, Ardsley offers investment advisory services to pooled investment vehicles operating as private investment funds. As described in Item 5.A, above, each Investor must meet certain suitability requirements. In addition, the minimum initial investment for the Ardsley Funds is $1,000,000, and the minimum additional contribution is $100,000. The minimum initial investment for the Renewable Energy Fund is $1,000,000, and the minimum additional contribution is $250,000. As stated in Item 4.A, the Employee Funds solely accept investments from Ardsley employees and personnel and the Advanced Healthcare Fund is open only to Ardsley employees, personnel, and Philip Hempleman’s family members. |
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| Sandisk Corp | 56.7 | ||
| Advanced Micro Devices Inc | 54.0 | ||
| Sezzle Inc | 36.9 | ||
| Ikonics Corp | 23.7 | ||
| BrightSpring Health Services Inc | 22.7 | ||
| eBay Inc | 22.3 | ||
| Sunrun Inc | 21.4 | ||
| JDS Uniphase Corp /CA/ | 18.6 | ||
| ARM Holdings PLC /UK | 16.6 | ||
| Shoals Technologies Group Inc | 16.5 | ||
| View All | |||
| Holdings by Sector ($M) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | Ardsley Ridgecrest Partners Fund LP | [2014-03-28] | 30.3 M | 26.3 M |
| Filed 2024-11-18 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Ardsley Offshore Fund Ltd | [2012-02-14] | 4.8 M | 15.2 M |
| Filed 2012-03-12 (D/A) · Exemption 506, 3(c)(1) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Ardsley Partners Institutional Fund LP | 2012-02-14 | 198.0 M | |
| HF | Ardsley Renewable Energy Offshore Fund Ltd | [2012-02-14] | 5.0 M | 4.7 M |
| Filed 2012-03-12 (D/A) · Exemption 506, 3(c)(1) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($M) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 7 | 895.3 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 7 | 895.3 |
| By Discretionary | ||
| Discretionary | 7 | 895.3 |
| Non-Discretionary | 0 | 0.0 |
| Total | 7 | 895.3 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.0 | |
| United States Persons | 895.3 | |
| Total | 7 | 895.3 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Neil Glass | Director | 20 | 9 | |
| Philip Hempleman | Executive Officer | 8 | 3 | |
| Ardsley Advisory Partners LP | Promoter | 8 | 3 | |
| Spencer Hempleman | Executive Officer | 8 | 3 | |
| Ardsley Partners I GP LLC | Executive Officer | 8 | 3 | |
| Ardsley Partners I | Executive Officer | 3 | 3 | |
| Willy Weber | Director | 3 | 2 | |
| Ardsley Advisory Partners | Promoter | 3 | 2 | |
| Steven Napoli | Director | 2 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0000900529] | |
| 3 | [0000900529] | |
| 4 | [0000900529] | |
| SC 13D | [0000900529] | |
| SC 13G | [0000900529] |
| Firm Profile (Form ADV) | |
|---|---|
| Discretionary AUM | $0.7B |
| Serves | Institutional |
| Fund Types | Hedge Fund |
| LEI | 549300GQR5ULS7W2C050 |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Marrone Bio Innovations Inc MBII
Warrant · derivative
|
2021-11-11 | Option exercise | 618,014 | $0.75 | 463,510 |
|
Marrone Bio Innovations Inc MBII
Common Stock
|
2021-11-11 | Option exercise | 618,014 | $0.75 | 463,510 |
|
Marrone Bio Innovations Inc MBII
Common Stock
|
2021-03-12 | Option exercise | 741,617 | $0.75 | 556,213 |
|
Marrone Bio Innovations Inc MBII
Warrant · derivative
|
2021-03-12 | Option exercise | 741,617 | $0.75 | 556,213 |
|
Marrone Bio Innovations Inc MBII
Common Stock
|
2020-12-31 | Other | 50,000 | $1.26 | 63,000 |
|
Marrone Bio Innovations Inc MBII
Common Stock
|
2020-12-31 | Other | 50,000 | $1.26 | 63,000 |
|
Marrone Bio Innovations Inc MBII
Common Stock
|
2020-12-14 | Option exercise | 1,648,037 | $0.75 | 1,236,028 |
|
Marrone Bio Innovations Inc MBII
Warrant · derivative
|
2020-12-14 | Option exercise | 1,648,037 | $0.75 | 1,236,028 |
|
Marrone Bio Innovations Inc MBII
Common Stock
|
2020-09-15 | Option exercise | 343,341 | ||
|
Marrone Bio Innovations Inc MBII
Warrant · derivative
|
2020-09-15 | Option exercise | 343,341 | $0.75 | 257,506 |
|
SunOpta Inc STKL
Common Stock
|
2020-08-18 | Sell | 2,300,000 | $6.00 | 13,800,000 |
|
SunOpta Inc STKL
Common Stock
|
2020-08-18 | Sell | 1,000,000 | $6.00 | 6,000,000 |
|
SunOpta Inc STKL
Common Stock
|
2020-08-06 | Sell | 12,500 | $6.77 | 84,625 |
|
SunOpta Inc STKL
Common Stock
|
2020-08-05 | Sell | 50,000 | $6.31 | 315,500 |
|
SunOpta Inc STKL
Common Stock
|
2020-08-05 | Sell | 25,000 | $6.56 | 164,000 |
|
SunOpta Inc STKL
Common Stock
|
2020-08-05 | Sell | 25,000 | $7.10 | 177,500 |
|
Marrone Bio Innovations Inc MBII
Common Stock
|
2020-05-01 | Option exercise | 429,176 | ||
|
Marrone Bio Innovations Inc MBII
Warrant · derivative
|
2020-05-01 | Option exercise | 429,176 | ||
|
Marrone Bio Innovations Inc MBII
Warrant · derivative
|
2020-04-29 | Grant | 741,617 | ||
|
Marrone Bio Innovations Inc MBII
Warrant · derivative
|
2020-04-29 | Grant | 1,648,037 | ||
| showing 20 of 83 most recent transactions | |||||